Biomica to Present at the 7th Microbiome Movement Drug Development Summit

Rhea-AI Summary

Biomica Ltd. announced its participation in the 7th Microbiome Movement Drug Development Summit, taking place from June 21-24, 2022, in Boston, MA. Dr. Elran Haber, CEO of Biomica, will join the opening panel on June 22, 2022. This summit is recognized as a key platform for microbiome drug developers, focusing on next-generation microbiome-based therapeutics and fostering industry collaborations. Biomica, a subsidiary of Evogene Ltd. (NASDAQ: EVGN), specializes in developing microbiome-based therapies targeting antibiotic-resistant bacteria and GI disorders.

Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference

REHOVOT, Israel, June 15, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting as part of a panel at the opening session of the 7^th Microbiome Movement Drug Development Summit taking place between June 21-24, 2022 in Boston, MA.

 

 

The event is known in the field as the most comprehensive forum for microbiome drug developers and an opportunity for the industry to take a collaborative approach, discuss next-generation microbiome-based therapeutics and establish new partnerships.

In attendance will be Dr. Elran Haber, CEO of Biomica. Dr. Haber will be part of the plenary opening industry leaders panel on June 22, 2022.

Dr. Haber will be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.  

About Biomica

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more information, please visit www.biomicamed.com.

Logo - https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg

Contacts

Lital Mamon 
Head of Marketing and PR 
IR@evogene.com
+972-8-931-2097

Kenny Green 
US Investor Relations 
IR@evogene.com
+1-212-378-8040

View original content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-7th-microbiome-movement-drug-development-summit-301568563.html

SOURCE Biomica Ltd.

FAQ

What is Biomica's role at the 7th Microbiome Movement Drug Development Summit?

Biomica will present as part of a panel at the opening session of the summit on June 22, 2022.

Who is representing Biomica at the conference?

Dr. Elran Haber, CEO of Biomica, will represent the company at the summit.

When is the 7th Microbiome Movement Drug Development Summit?

The summit will take place from June 21-24, 2022.

What is the focus of Biomica's research?

Biomica focuses on developing microbiome-based therapeutics for antibiotic-resistant bacteria and gastrointestinal disorders.

How can I arrange a meeting with Dr. Elran Haber at the summit?

Interested parties should contact Biomica's investor or public relations team to arrange a one-on-one meeting.

What is the stock symbol for Evogene Ltd.?

The stock symbol for Evogene Ltd. is EVGN.